Cargando…

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials

INTRODUCTION: It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis. AIM: This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis. MATERIAL AND METHODS: Sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junqiao, Yang, Yuanjuan, Yang, Haitao, Fu, Xiaojuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704456/
https://www.ncbi.nlm.nih.gov/pubmed/36457683
http://dx.doi.org/10.5114/ada.2022.114925
_version_ 1784840057873498112
author Wang, Junqiao
Yang, Yuanjuan
Yang, Haitao
Fu, Xiaojuan
author_facet Wang, Junqiao
Yang, Yuanjuan
Yang, Haitao
Fu, Xiaojuan
author_sort Wang, Junqiao
collection PubMed
description INTRODUCTION: It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis. AIM: This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis. MATERIAL AND METHODS: Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library were systematically searched through July 2021. We included randomized controlled trials (RCTs) assessing the effect of abrocitinib 100 mg versus 200 mg for patients with atopic dermatitis. RESULTS: Four RCTs were included in the meta-analysis. Compared with abrocitinib 100 mg for atopic dermatitis, abrocitinib 200 mg had a remarkably positive impact on IGA response (OR = 1.78; 95% CI: 1.39–2.28; p < 0.00001), EASI-75 (OR = 2.03; 95% CI: 1.60–2.57; p < 0.00001), NRS response (OR = 1.97; 95% CI: 1.27–3.08; p = 0.003), and adverse events (OR = 1.43; 95% CI: 1.11–1.84; p = 0.005), but it showed no obvious influence on serious adverse events (OR = 0.59; 95% CI: 0.25–1.37; p = 0.22). CONCLUSIONS: Abrocitinib 200 mg is better than abrocitinib 100 mg for the treatment of atopic dermatitis.
format Online
Article
Text
id pubmed-9704456
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-97044562022-11-30 Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials Wang, Junqiao Yang, Yuanjuan Yang, Haitao Fu, Xiaojuan Postepy Dermatol Alergol Original Paper INTRODUCTION: It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis. AIM: This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis. MATERIAL AND METHODS: Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library were systematically searched through July 2021. We included randomized controlled trials (RCTs) assessing the effect of abrocitinib 100 mg versus 200 mg for patients with atopic dermatitis. RESULTS: Four RCTs were included in the meta-analysis. Compared with abrocitinib 100 mg for atopic dermatitis, abrocitinib 200 mg had a remarkably positive impact on IGA response (OR = 1.78; 95% CI: 1.39–2.28; p < 0.00001), EASI-75 (OR = 2.03; 95% CI: 1.60–2.57; p < 0.00001), NRS response (OR = 1.97; 95% CI: 1.27–3.08; p = 0.003), and adverse events (OR = 1.43; 95% CI: 1.11–1.84; p = 0.005), but it showed no obvious influence on serious adverse events (OR = 0.59; 95% CI: 0.25–1.37; p = 0.22). CONCLUSIONS: Abrocitinib 200 mg is better than abrocitinib 100 mg for the treatment of atopic dermatitis. Termedia Publishing House 2022-03-27 2022-10 /pmc/articles/PMC9704456/ /pubmed/36457683 http://dx.doi.org/10.5114/ada.2022.114925 Text en Copyright: © 2022 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Wang, Junqiao
Yang, Yuanjuan
Yang, Haitao
Fu, Xiaojuan
Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
title Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
title_full Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
title_fullStr Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
title_full_unstemmed Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
title_short Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
title_sort abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704456/
https://www.ncbi.nlm.nih.gov/pubmed/36457683
http://dx.doi.org/10.5114/ada.2022.114925
work_keys_str_mv AT wangjunqiao abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials
AT yangyuanjuan abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials
AT yanghaitao abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials
AT fuxiaojuan abrocitinib100mgversus200mgforatopicdermatitisametaanalysisofrandomizedcontrolledtrials